首页> 外文OA文献 >Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial

【2h】

Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial

机译：随机，安慰剂对照，FosapRepitant，Ondansetron，Dexamethasone（喜欢的）与Fond Plus Olanzapine（FONE-O）进行血液学恶性肿瘤患者的血液学恶性肿瘤患者呕吐，ondansetron，ondansetron（Fond-O）的试验。接受高均匀化疗和造血细胞移植的血液学恶性肿瘤患者方案：FOND-O试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Amber B. Clemmons; Julianne Orr; Benjamin Andrick; Arpita Gandhi; Claude Sportes; David DeRemer;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial [J] . Amber B. Clemmons, Julianne Orr, Benjamin Andrick, Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2018,第10期

机译：随机，安慰剂对照，FosapRepitant，Ondansetron，Dexamethasone（喜欢的）与Fond Plus Olanzapine（FONE-O）进行血液学恶性肿瘤患者的血液学恶性肿瘤患者呕吐，ondansetron，ondansetron（Fond-O）的试验。接受高均匀化疗和造血细胞移植的血液学恶性肿瘤患者方案：FOND-O试验
2. APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide–based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the Phase III randomized MAGIC trial [J] . Ian D Schnadig, Richy Agajanian, Christopher Dakhil, Cancer Management and Research . 2017,第4期

机译：APF530与恩丹西酮，均采用指南推荐的三药方案，用于预防因蒽环类抗生素加环磷酰胺为基础的高致呕性化疗方案而导致的化疗引起的恶心和呕吐：III期随机MAGIC试验的事后亚组分析
3. Ramosetron Versus Ondansetron in Combination With Aprepitant and Dexamethasone for the Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Randomized Phase III Trial, KCSG PC10-21 [J] . The oncologist . 2015,第12期

机译：Ramosetron与Ondansetron联合Aprepitant和地塞米松预防高度致呕性化疗所致的恶心和呕吐：多中心，随机III期试验，KCSG PC10-21
4. APF530 versus ondansetron each in a guideline-recommended three-drug regimen for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide–based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the Phase III randomized MAGIC trial [O] . Ian D Schnadig, Richy Agajanian, Christopher Dakhil, 2017

机译：APF530与昂丹司琼分别采用一种指南推荐的三药方案用于预防因蒽环类抗生素加环磷酰胺的高度致呕性化疗方案而导致的化疗引起的恶心和呕吐：III期随机MAGIC试验的事后亚组分析
5. A Prospective, Randomized Double-Blind Phase III Trial Of Aprepitant vs. Placebo Plus Oral Ondansetron And Dexamethasone For The Prevention Of Nausea And Vomiting (N/V) Associated With Highly Emetogenic Preparative Regimens Prior To Hematopoietic Stem Cell Transplantation (HSCT) [O] . Stiff P.J., Fox-Geiman M., Kiley K., 2010

机译：Aprepitant对比安慰剂加口服Ondansetron和Dexamethasone的前瞻性，随机双盲III期试验，用于预防造血干细胞移植（HSCT）引起的催吐和呕吐（N / V）与高度催吐的制备药物相关。

著录项

相似文献

相关主题

期刊订阅